Shares of Loxo Oncology Inc (NASDAQ:LOXO) rose 0% during mid-day trading on Wednesday . The stock traded as high as $102.78 and last traded at $100.92. Approximately 957,300 shares were traded during mid-day trading, an increase of 187% from the average daily volume of 333,587 shares. The stock had previously closed at $100.92.

LOXO has been the topic of several research reports. Citigroup lowered their price target on shares of Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, November 16th. BidaskClub raised shares of Loxo Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, January 9th. William Blair began coverage on shares of Loxo Oncology in a report on Tuesday, November 28th. They set an “outperform” rating on the stock. Finally, JMP Securities raised shares of Loxo Oncology from a “market perform” rating to an “outperform” rating and upped their target price for the stock from $77.18 to $95.00 in a report on Tuesday, November 14th. One equities research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $97.33.

The company has a market capitalization of $2,812.33, a price-to-earnings ratio of -17.31 and a beta of 2.57.

In other Loxo Oncology news, VP Jennifer Burstein sold 1,700 shares of the business’s stock in a transaction that occurred on Monday, November 27th. The shares were sold at an average price of $74.82, for a total value of $127,194.00. Following the completion of the transaction, the vice president now owns 1,700 shares of the company’s stock, valued at approximately $127,194. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Avi Z. Naider sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, January 22nd. The stock was sold at an average price of $100.00, for a total transaction of $1,500,000.00. Following the completion of the transaction, the director now directly owns 141,118 shares of the company’s stock, valued at approximately $14,111,800. The disclosure for this sale can be found here. Insiders have sold a total of 1,628,396 shares of company stock worth $125,989,430 in the last ninety days. 27.80% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in LOXO. QS Investors LLC purchased a new position in Loxo Oncology in the 4th quarter worth approximately $118,000. Quantbot Technologies LP purchased a new position in Loxo Oncology in the 3rd quarter worth approximately $122,000. Ameritas Investment Partners Inc. grew its stake in Loxo Oncology by 31.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after buying an additional 419 shares in the last quarter. Cambridge Investment Research Advisors Inc. purchased a new position in Loxo Oncology in the 3rd quarter worth approximately $212,000. Finally, Amalgamated Bank purchased a new position in Loxo Oncology in the 3rd quarter worth approximately $268,000.

TRADEMARK VIOLATION WARNING: “Loxo Oncology (LOXO) Stock Price Up 0%” was published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this piece of content on another publication, it was copied illegally and republished in violation of United States & international trademark and copyright law. The original version of this piece of content can be read at https://theolympiareport.com/2018/02/14/loxo-oncology-loxo-stock-price-up-0.html.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.